VHL Ligase Ligands for PROTAC Applications

Introduction

Proteolysis targeting chimeras (PROTACs) are therapeutic agents designed to induce selective intracellular degradation of pathogenic proteins. They consist of two covalently linked ligands: one binds to the target protein, while the other recruits an E3 ubiquitin ligase to tag the unwanted protein for degradation.[1] Ciulli and coworkers developed several efficient small-molecule ligands that recruit the von Hippel-Lindau (VHL) E3 ubiquitin ligase for the degradation tagging, among them VH032, VH101, and VH298 with nanomolar binding affinity.[1,2] Few PROTACs utilizing the VHL ligase – DT2216, PRT3789, ASP3082, and KT333 – have advanced to clinical trials.[1,3,4] At Enamine, we provide building blocks related to VH101, including diverse attachment sites and structural modifications. Additionally, we offer support for the synthesis of custom PROTAC molecules that feature a range of linkers and protein binders.



We offer: over 500 von Hippel-Lindau ligands from stock.

Visit our dedicated PROTAC page here:


EN300-45603506


EN300-45608424


EN300-45603507


EN300-44826220


EN300-28334169


EN300-28309175


EN300-28332243


EN300-52058996


EN300-28320939


EN300-33295516


EN300-46966989


EN300-28332897


EN300-28320945


EN300-28266491


EN300-26966947


EN300-6729776


EN300-52369576


EN300-22990404


EN300-43379471


EN300-52195365

References

1. C. Diehl and A. Ciulli. *Chem. Soc. Rev.* **2022**, *51*, 8216.
2. P. Soares et al. *J. Med. Chem.* **2018**, *61*, 599.
3. X. Han et al. *J. Med. Chem.* **2019**, *62*, 941.
3. T. Yoshinari et al. *Commun. Chem.* **2025**, *8*, 254.